Akèy › Kansè nan tete › Indiana
Etid klinik pou Kansè nan tete nan Indiana
35 etid pou Kansè nan tete ap chèche patisipan nan sit nan Indiana.
Vil nan Indiana
- Indianapolis20 etid
- Hammond9 etid
- Fort Wayne7 etid
- South Bend5 etid
- Evansville3 etid
- Gary3 etid
- Richmond3 etid
Tèks ofisyèl etid la (Anglè)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Investigative Clinical R of Indiana, Indianapolis
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Fort Wayne
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07205822Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06625775Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 45 · Fanm · Mizajou Oct 1, 2026 · NCT05557877Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Community Health Network, Indianapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06324357A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne
- Franciscan Health ( Site 0077), Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwest Cancer Center, Dyer
- Indiana University, Indianapolis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Indiana University Health University Hospital, Indianapolis
- Deaconess GI Specialty Center, Newburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Indiana University (IU) School of Medicine, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Northwest Cancer Centers, PC, Dyer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Community Health Network, Inc, Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT05846789Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Goshen Center for Cancer Care, Goshen
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- IU Health West Hospital, Avon
- IU Health North Hospital, Carmel
- UChicago Medicine Northwest Indiana, Crown Point
- ak 12 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Northwest Cancer Center, Dyer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612HER2 Vaccine for Locally Advanced Breast Cancer
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06949410HER-2 B Cell Peptide Vaccine
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06414733E-Mindfulness Approaches for Living After Breast Cancer
- Goshen Center for Cancer Care, Goshen
- Baptist Health Floyd, New Albany
- Memorial Hospital of South Bend, South Bend
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Exercise in Metastatic Breast Cancer: EMBody
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 27, 2026 · NCT05468034De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Northwest Cancer Center - Main Campus, Crown Point
- UChicago Medicine Northwest Indiana, Crown Point
- Northwest Oncology LLC, Dyer
- ak 9 plis
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
- Indiana University, Indianapolis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT04841148Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05735080Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Woodland Cancer Care Center, Michigan City
- Reid Health, Richmond
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- Research Site, Indianapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06956690NearWave Optical Molecular Monitoring
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Feb 17, 2026 · NCT06744465EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Deaconess Chancellor Center for Oncology, Newburgh
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06401421cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Saint Elizabeth Health - Lafayette East, Lafayette
- Franciscan Health Mooresville, Mooresville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Community Health Network, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2025 · NCT05216432MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Parkview Health, Fort Wayne
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2025 · NCT03053193A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Northwest Cancer Center, Dyer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 19, 2025 · NCT06568692BostonGene and Exigent Genomic INsight Study
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 17, 2025 · NCT06272864Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.